- Home
- VRXA vs WIA Comparison
VRXA vs WIA Comparison
Compare VRXA & WIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRXA | WIA |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.4M | 178.2M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRXA | WIA |
|---|---|---|
| Price | $1.17 | $7.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 109.4K | 51.6K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.29% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $7.45 |
| 52 Week High | $4.50 | $8.54 |
Technical Indicators
Market Signals| Indicator | VRXA | WIA |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | 28.55 |
| Support Level | N/A | N/A |
| Resistance Level | $1.99 | $8.21 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.17 | 30.77 |
Price Performance
Historical ComparisonAbout VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.